BCM
CKPT

BlueCrest Capital Management’s Checkpoint Therapeutics CKPT Stock Holding History

BlueCrest Capital Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,034
Closed -$45K – 1526
2018
Q1 		$45K Buy
+1,034
New +$44.9K ﹤0.01% 1424

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
BII
Bainco International Investors Boston, Massachusetts $873M AUM 30.2% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlueCrest Capital Management's CKPT Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2018, closing a stake of 1,034 shares — an estimated $45K sold.

BlueCrest Capital Management first reported a position in CKPT in Q1 2018 and held it in 1 quarter. The position peaked at $45K in Q1 2018. 10 funds tracked by Wall St. Rank hold CKPT as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Checkpoint Therapeutics position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,034 Checkpoint Therapeutics shares in Q2 2018, an estimated $45K.
  • BlueCrest Capital Management first reported a position in Checkpoint Therapeutics in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Checkpoint Therapeutics position peaked at $45K in Q1 2018.
  • 10 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.